We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Thyroid Nodule Test Could Reduce Unnecessary Surgeries

By HospiMedica staff writers
Posted on 29 May 2008
By testing suspicious thyroid nodules using fine needle aspiration (FNA) for the presence of galectin-3--a lectin molecule that binds specific sugars--a substantial number of unnecessary surgical procedures could be eliminated, claims a new study. More...


Researchers at Sant'Andrea Hospital (Rome, Italy) performed an Italian national study in 465 subjects who had thyroid nodules larger than 1 cm in diameter for which malignancy could not be determined. The subjects enrolled between Jun 1, 2003 and August 30, 2006, were mostly women aged 21 to 76 years, with an average age of 50. The nodules were removed and analyzed with histological testing to determine whether they were cancerous or not. These results were compared to the results of galectin-3 tests.

The results showed that in 71% of the nodules, galectin-3 was not expressed. Of these galectin-3 negative nodules, 85% of them were, as predicted, benign, but 9% were cancerous and thus indicated potential false negatives. Of these, 28% showed different galectin-3 expression when tested post-operatively, suggesting that the false result could have been caused by technical problems in the test. The total sensitivity of the test was 78%, and specificity was 93%. The positive predictive value was 82% and the negative predictive value was 91%. The study was published in the May 19, 2008, issue of The Lancet Oncology.

"The galectin-3 method proposed here does not replace conventional FNA cytology, but represents a complementary diagnostic method for those follicular nodules that remain indeterminate. The correct approach for this preoperative characterization of thyroid nodules always needs careful multidisciplinary assessment of each patient, according to published guidelines,” concluded lead author Armando Bartolazzi, M.D., Ph.D., and colleagues of the department of pathology.

Galectin-3, (Gal-3), a member of the beta-galactoside binding lectin family, is an anti-apoptotic protein that protects T cells, macrophages, and breast carcinoma cells from death triggered by a variety of agents. It is not normally found in the cytoplasm of healthy thyroid cells; if it is abnormally present, it can block cell death, leading to the eventual development of cancer.


Related Links:
Sant'Andrea Hospital

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.